Page 1 of Clinical Trials for Metastatic Gastroesophageal Adenocarcinoma, 75 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Completed
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Last Updated: January 17, 2012
Condition(s): Stomach Neoplasms; Esophageal Neoplasms
2
Recruiting
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
Last Updated: May 8, 2012
Condition(s): Esophageal; Gastrooesophageal Cancer; Gastric Cancer
3
Recruiting
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
Last Updated: February 29, 2012
Condition(s): Adenocarcinoma of the Esophagus; Diffuse Adenocarcinoma of the Stomach; Intestinal Adenocarcinoma of the Stomach; Mixed Adenocarcinoma of the Stomach; Stage IV Esophageal Cancer; Stage IV Gastric Cancer
4
Recruiting
Combination Chemotherapy and Bevacizumab in Treating Patients With Recurrent, Unresectable, or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, or Esophageal Cancer
Last Updated: July 7, 2009
Condition(s): Esophageal Cancer; Gastric Cancer
5
Recruiting
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma
Last Updated: September 28, 2011
Condition(s): Malignant Neoplasm of Esophagus; Malignant Neoplasm of Stomach
6
Active, not recruiting
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
Last Updated: April 26, 2012
Condition(s): Gastric Adenocarcinoma; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma
7
Recruiting
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Last Updated: April 27, 2012
Condition(s): Advanced Nonhematological Malignancies; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Head and Neck Squamous Cell Carcinoma; Gastroesophageal Adenocarcinoma
8
Completed
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
Last Updated: February 17, 2006
Condition(s): Gastroesophageal Adenocarcinoma; Gastric Adenocarcinoma
9
Completed
Docetaxel + Oxaliplatin + S-1 in Neoadjuvant Gastric Cancer
Last Updated: May 15, 2012
Condition(s): Esophageal Neoplasms
10
Recruiting
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Last Updated: May 23, 2012
Condition(s): Gastroesophageal Junction Adenocarcinoma; Gastric Cancer
11
Active, not recruiting
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Last Updated: February 1, 2012
Condition(s): Gastric Cancer; Esophageal Neoplasms
12
Active, not recruiting
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Last Updated: January 29, 2011
Condition(s): Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
13
Active, not recruiting
Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
Last Updated: January 20, 2011
Condition(s): Gastrointestinal Cancer
14
Recruiting
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
Last Updated: May 23, 2011
Condition(s): Metastatic Gastric Cancer; Adenocarcinoma of the Gastro-oesophageal Junction
15
Completed
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
Last Updated: March 1, 2012
Condition(s): Stomach Neoplasms; Esophageal Neoplasms
16
Completed
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Last Updated: December 13, 2009
Condition(s): Gastric Cancer
17
Recruiting
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
Last Updated: April 4, 2012
Condition(s): Gastrointestinal Neoplasm; Gastric Adenocarcinoma
18
Recruiting
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Last Updated: June 23, 2011
Condition(s): Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
19
Recruiting
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Last Updated: April 30, 2012
Condition(s): Stomach Neoplasms; Esophageal Neoplasms
20
Active, not recruiting
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
Last Updated: September 23, 2011
Condition(s): Gastrointestinal Diseases

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Metastatic+Gastroesophageal+Adenocarcinoma

Page 1 of Clinical Trials for Metastatic Gastroesophageal Adenocarcinoma, 75 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About